1. Home
  2. GIB vs ABVX Comparison

GIB vs ABVX Comparison

Compare GIB & ABVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo CGI Inc.

GIB

CGI Inc.

HOLD

Current Price

$69.35

Market Cap

14.4B

ML Signal

HOLD

Logo Abivax SA American

ABVX

Abivax SA American

HOLD

Current Price

$95.06

Market Cap

11.9B

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
GIB
ABVX
Founded
1976
2013
Country
Canada
France
Employees
94000
N/A
Industry
Professional Services
Sector
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
14.4B
11.9B
IPO Year
1999
2022

Fundamental Metrics

Financial Performance
Metric
GIB
ABVX
Price
$69.35
$95.06
Analyst Decision
Hold
Buy
Analyst Count
3
13
Target Price
$112.00
$131.31
AVG Volume (30 Days)
306.0K
1.1M
Earning Date
04-29-2026
03-23-2026
Dividend Yield
0.70%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$8.33
$52.14
Revenue Next Year
$2.96
$4,132.27
P/E Ratio
$13.59
N/A
Revenue Growth
N/A
N/A
52 Week Low
$59.63
$69.81
52 Week High
$95.20
$148.83

Technical Indicators

Market Signals
Indicator
GIB
ABVX
Relative Strength Index (RSI) N/A N/A
Support Level N/A N/A
Resistance Level N/A N/A
Average True Range (ATR) 0.00 0.00
MACD 0.00 0.00
Stochastic Oscillator 0.00 0.00

Price Performance

Historical Comparison
GIB
ABVX

About GIB CGI Inc.

CGI is a Canada-based IT-services provider with an embedded position in North America and Europe. The company is one of the major IT suppliers to different levels of government around the world. It offers a broad portfolio of services such as consulting, systems integration, application maintenance, and business process services to governments and the private sector. With offices in over 40 countries, CGI follows a balanced global delivery model with most consultants in client proximity.

About ABVX Abivax SA American

Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. The company is evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two common forms are UC and CD. The Group operates in a single operating segment: R&D of pharmaceutical products in order to market them in the future.

Share on Social Networks: